Search clinical trials for: GSK1278863

Total 24 results

GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Anaemia

Japan
GlaxoSmithKline

Completed

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

Anaemia

United States
GlaxoSmithKline

Terminated

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Anaemia

United States
GlaxoSmithKline
PPD

Completed

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Anaemia

United States, Canada, Germany
GlaxoSmithKline

Completed

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Anaemia

United States, Australia, Korea, Republic of, Canada, Czechia, Norway, Spain, United Kingdom, Russian Federation, Germany, Sweden, Denmark, Poland, France, Hungary, Japan
GlaxoSmithKline
PPD

Completed

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

United States, Germany, Canada, Sweden, Denmark, Norway
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

Anemia

United States
GlaxoSmithKline
Octagon Research Solutions, Incoporated

Completed

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil) (DDI)

Anaemia

India
GlaxoSmithKline

Completed

Daprodustat Hepatic Impairment Study

Anaemia

United States
GlaxoSmithKline

Completed

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Surgical Procedures

United States, Canada
GlaxoSmithKline

Completed

3 Month PHI PAD PoM Study

Vascular Disease, Peripheral

United States
GlaxoSmithKline

Completed

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

Tendon Injuries

United States
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Anaemia

Spain, United States, Russian Federation, Canada, Germany
GlaxoSmithKline

Completed

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Anaemia

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Anaemia

United States, Australia, Canada, Hungary, Spain, Sweden, Czechia, Germany, United Kingdom, Korea, Republic of, Russian Federation, France, Denmark, Poland, Japan
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

Japan
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

Wound Healing

United States
GlaxoSmithKline

Completed

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Anaemia

United States
GlaxoSmithKline

Completed

Absorption and Elimination of Radiolabeled Daprodustat

Anaemia

United Kingdom
GlaxoSmithKline

Completed

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

Anaemia

United States
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Anaemia

United States, Australia, Korea, Republic of, Spain, Taiwan, Bulgaria, Canada, Italy, Russian Federation, Ukraine, Argentina, Belgium, France, Philippines, South Africa, Thailand, Israel, Sweden, Singapore, Czechia, Hong Kong, Net... and more
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anaemia | Aspergillosis, Allergic Bronchopulmonary

Australia, Korea, Republic of, Spain, United States, Taiwan, Bulgaria, Mexico, Ukraine, Argentina, Belgium, South Africa, Singapore, Austria, Canada, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, Germany, Romania and more
GlaxoSmithKline

Completed

Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

Anaemia

Japan
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Anaemia

United States, Canada, France, Russian Federation, Spain, Australia, United Kingdom, Romania, Brazil, Korea, Republic of, Italy, Poland, Argentina, Mexico

3

Subscribe